Stein Tomasz, Robak Tadeusz, Biernat Wojciech, Robak Ewa
Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland.
Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
J Clin Med. 2024 Jan 31;13(3):823. doi: 10.3390/jcm13030823.
One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders. This review article summarises the clinical evidence supporting the current treatment options for these diseases. Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date.
皮肤T细胞淋巴瘤最常见的亚组之一是原发性皮肤CD30阳性淋巴增殖性疾病。该组包括淋巴瘤样丘疹病（LyP）和原发性皮肤间变性大细胞淋巴瘤（pcALCL），以及一些临界病例。最近，在了解这些疾病的遗传学和治疗方面取得了重大进展。这篇综述文章总结了支持这些疾病当前治疗选择的临床证据。近年来，新型药物已引入临床实践；其中大多数靶向CD30，如抗CD30单克隆抗体和偶联抗体（本妥昔单抗）、双特异性抗体和细胞疗法，特别是抗CD30嵌合抗原受体T细胞（CAR-T细胞）。本文简要回顾了使CD30成为良好治疗靶点的生物学特性，并描述了迄今为止出现的抗CD30疗法。
